CD274 and invasive carcinoma: A recent study, performed in WLWH and non-HIV patients with in-situ and invasive carcinomas, reported lower (16.7%) PD-L1 expression in both groups using SP263 TPS ≥ 50% and 22C3 CPS ≥ 157.